Preventive effect of gastrodin on cognitive decline after cardiac surgery with cardiopulmonary bypass: A double-blind, randomized controlled study

Abstract

Cognitive decline is a common complication after cardiac surgery with cardiopulmonary bypass (CPB), but as such no pharmacological therapy has been shown to be efficacious in preventing the decline. However, gastrodin has been shown to have multi-pharmacological effects on neurological functions. We undertook this study to test the hypothesis that gastrodin would potentially prevent CPB-associated neurocognitive decline. We randomly assigned 200 patients undergoing mitral valve replacement surgery to receive either gastrodin (40 mg/kg) or saline after the induction of anesthesia and subsequently evaluated cognitive function before surgery, at discharge, and at 3rd month after surgery by using a battery of five neurocognitive tests, or adverse effects of gastrodin postoperatively. Neurocognitive decline in postoperative function was defined as a drop of 1 SD or more in the scores on tests of any one of the four domains of cognitive function. Cognitive decline occurred in 9% of the patients in the gastrodin group in contrast to 42% in the control group (P<0.01) at discharge. Cognitive outcome could be determined at 3rd month in 87 patients in the gastrodin group and 89 in the control group. Cognitive decline was detected in 6% in the gastrodin group and 31% in the control group (P<0.01). The incidences of possible adverse effects were similar between two groups. These results indicate that gastrodin is an effective and a safe drug for the prevention of neurocognitive decline in patients undergoing mitral valve replacement surgery with CPB.

Keywords

gastrodin / cardiopulmonary bypass / cognitive decline

References

[1] NewmanM.F., KirchnerJ.L., Phillips-ButeB., et al.. Longitudinal assessment of neurocognitive function after coronary artery bypass surgery. N Engl J Med, 2001, 344(6): 395-402

[2] SelnesO.A., GoldsboroughM.A., BorowiczL.M., et al.. Neurobehavioral sequelae of cardiopulmonary bypass. Lancet, 1999, 353(9164): 1601-1606

[3] LundC., HolP.K., LundbladR., et al.. Comparison of cerebral embolization during off-pump and on-pump coronary artery bypass surgery. Ann Thorac Surg, 2003, 76(3): 765-770

[4] BrownW.R., MoodyD.M., ChallaV.R., et al.. Longer duration of cardiopulmonary bypass is associated with greater numbers of cerebral microemboli. Stoke, 2000, 31(3): 707-713

[5] SatoY., LaskowitzD.T., BennettE.R., et al.. Differential cerebral gene expression during cardiopulmonary bypass in the rat: evidence for apoptosis?. Anesth Analg, 2002, 94(6): 1389-1394

[6] SiesjöB.K., ZhaoQ., PahlmarkK., et al.. Glutamate, calcium, and free radicals as mediators of ischemic brain damage. Ann Thorac Surg, 1995, 59(5): 1316-1320

[7] MurkinJ.M.. Attenuation of neurologic injury during cardiac surgery. Ann Thorac Surg, 2001, 72(5): S1838-S1844

[8] TsengE.E., BrockM.V., KwonC.C., et al.. Increased intracerebral excitatory amino acids and nitric oxide after hypothermic circulatory arrest. Ann Thorac Surg, 1999, 67(2): 371-376

[9] ChakravarthyM., ManjunathV., JavaliV., et al.. Neurocognitive behavior changes in patients undergoing off pump coronary artery bypass surgery: A prospective observational study. J Anaesth Clin Pharmacol, 2008, 24(1): 45-52

[10] RajaP.V., BlumenthalJ.A., DoraiswamyM.P.. Cognitive deficits following coronary artery bypass grafting: prevalence, prognosis, and therapeutic strategies. CNS Spect, 2004, 9(10): 763-772

[11] YuS.J., KimJ.R., LeeC.K., et al.. Gastrodia elata Blume and an active component, p-hydroxybenzyl alcohol reduce focal ischemic brain injury through antioxidant related gene expressions. Biol Pharm Bull, 2005, 28(6): 1016-1020

[12] HsiehC.L., ChenC.L., TangN.Y., et al.. Gastrodia elata BL mediates the suppression of nNOS and microglia activation to protect against neuronal damage in kainic acid-treated rats. Am J Chin Med, 2005, 33(4): 599-611

[13] KimH.J., LeeS.R., MoonK.D.. Ether fraction of methanol extracts of Gastrodia elata, medicinal herb protects against neuronal cell damage after transient global ischemia in gerbils. Phytother Res, 2003, 17(8): 909-912

[14] KimH.J., MoonK.D., OhS.Y., et al.. Ether fraction of methanol extracts of Gastrodia elata, a traditional medicinal herb, protects against kainic acid-induced neuronal damage in the mouse hippocampus. Neurosci Lett, 2001, 314(1–2): 65-68

[15] LeeY.S., HaJ.H., YongC.S., et al.. Inhibitory effects of constituents of Gastrodia elata Bl. on glutamate -induced apoptosis in IMR-32 human neuroblastoma cells. Arch Pharm Res, 1999, 22(4): 404-409

[16] HuangN.K., LinY.L., ChengJ.J., et al.. Gastrodia elata prevents rat pheochromocytoma cells from serum-deprived apoptosis: the role of the MAPK family. Life Sci, 2004, 75(13): 1649-1657

[17] AnderssonM., BergendorffO., NielsenM., et al.. Inhibition of kainic acid binding to glutamate receptors by extracts of Gastrodia. Phytochemistry, 1995, 38(4): 835-836

[18] HaJ.H., LeeD.U., LeeJ.T., et al.. 4-Hydroxybenzaldehyde from Gastrodia elata B1 is active in the antioxidation and GABAergic neuromodulation of the rat brain. J Ethnopharmacol, 2000, 73(1–2): 329-333

[19] LiH.B., ChenF.. Preparative isolation and purification of gastrodin from the Chinese medicinal plant Gastrodia elata by high-speed counter-current chromatography. J Chromatogr A, 2004, 1052(1–2): 229-232

[20] LinL.Y., ChenY.F., TsaiT.R., et al.. Analysis of brain distribution and biliary excretion of a nutrient supplement, gastrodin, in rat. Anal Chim Acta, 2007, 590(2): 173-179

[21] XuX., LuY., BieX.. Protective effects of gastrodin on hypoxia-induced toxicity in primary cultures of rat cortical neurons. Planta Med, 2007, 73(7): 650-654

[22] ZengX., ZhangS., ZhangL., et al.. A study of the neuroprotective effect of the phenolic glucoside gastrodin during cerebral ischemia in vivo and in vitro. Planta Med, 2006, 72(15): 1359-1365

[23] ZengX., ZhangY., ZhangS., et al.. A microdialysis study of effects of gastrodin on neurochemical changes in the ischemic/reperfused rat cerebral hippocampus. Biol Pharm Bull, 2007, 30(4): 801-804

[24] HsiehM.T., WuC.R., ChenC.F.. Gastrodin and p-hydroxy benzyl alcohol facilitate memory consolidation and retrieval, but not acquisition, on the passive avoidance task in rats. J Ethnopharmacol, 1997, 56(1): 45-54

[25] ZhangS., WangS., LiQ., et al.. Capillary leak syndrome in children with C4A-deficiency undergoing cardiac surgery with cardiopulmonary bypass: a double-blind, randomized controlled study. Lancet, 2005, 366(9485): 556-562

[26] ZhangS., WangS., YaoS.. Evidence for development of capillary leak syndrome associated with cardiopulmonary bypass in pediatric patients with the homozygous C4A null phenotype. Anesthesiology, 2004, 100(6): 1387-1393

[27] MurkinJ.M., NewmanS.P., StumpD.A., et al.. Statement of consensus of neurobehavioral outcomes after cardiac surgery. Ann Thorac Surg, 1995, 59(5): 1289-1295

[28] RasmussenL.S., LarsenK., HouxP., et al.. The assessment of postoperative cognitive function. Acta Anaesthesiol Scand, 2001, 45(3): 275-289

[29] NewmanM.F., GrocottH.P., MathewJ.P., et al.. Report of the substudy of assessing the impact of neurocognitive function on quality of life 5 years after cardiac surgery. Stoke, 2001, 32(12): 2874-2881

[30] GrocottH.P., MackensenG.B., GrigoreA.M., et al.. Postoperative hyperthermia is associated with cognitive dysfunction after coronary artery bypass graft surgery. Stoke, 2002, 33(2): 537-541

[31] WangX., YaoS., KirkpatrickB., et al.. Psychopathology and neuropsychological impairment in deficit and nondeficit schizophrenia of Chinese origin. Psychiatry Res, 2008, 158(2): 195-205

[32] BrækkenS.K., ReinvangI., RussellD., et al.. Association between intraoperative cerebral microembolic signals and postoperative neuropsychological deficit: comparison between patients with cardiac valve replacement and patients with coronary artery bypass grafting. J Neurol Neurosurg Psychiatry, 1998, 65(4): 573-576

[33] van DijkD., JansenE.W.L., HijmanR., et al.. Cognitive outcome after off-pump and on-pump coronary artery bypass graft surgery, a randomized trial. JAMA, 2002, 287(11): 1405-1412

[34] JonssonH., JohnssonP., AllingC., et al.. S100beta after coronary artery surgery: release pattern, source of contamination, and relation to neuropsychological outcome. Ann Thorac Surg, 1999, 68(6): 2202-2208

[35] HerrmannM., EbertA.D., GalazkyI., et al.. Neurobehavioral outcome prediction after cardiac surgery: role of neurobiochemical markers of damage to neuronal and glial brain tissue. Stroke, 2000, 31(3): 645-650

[36] van DijkD., SpoorM., HijmanR., et al.. Cognitive and cardiac outcomes 5 years after off-pump vs on-pump coronary artery bypass graft surgery. JAMA, 2007, 297(7): 701-708

[37] NewmanM.F., CroughwellN.D., WhiteW.D., et al.. Pharmacologic electroencephalographic suppression during cardiopulmonary bypass: a comparison of thiopental and isoflurane. Anesth Analg, 1998, 86(2): 246-251

[38] SelnesO.A., GoldsboroughM.A., BorowiczL.M.Jr, et al.. Determinants of cognitive change after coronary artery bypass surgery: a multifactorial problem. Ann Thorac Surg, 1999, 67(6): 1669-1676

[39] JungJ.W., YoonB.H., OhH.R., et al.. Anxiolytic-like effects of Gastrodia elata and its phenolic constituents in mice. Biol Pharm Bull, 2006, 29(2): 261-265

[40] GaoZ., TanT., ZhongY., et al.. Study of the mechanism of gastrodin and derivatives of gastrodigenin. Hua Xi Yi Ke Da Xue Xue Bao (Chinese), 1991, 22(1): 79-82